FFO
MRVI icon

Fortitude Family Office’s Maravai LifeSciences MRVI Stock Holding History

Fortitude Family Office’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-276
Closed -$610 – 2094
2025
Q1 		$610 Hold
276
– – ﹤0.01% 1072
2024
Q4 		$1.5K Buy
+276
New +$1.78K ﹤0.01% 1073
2024
Q3 		– Sell
-154
Closed -$1.1K – 1249
2024
Q2 		$1.1K Buy
+154
New +$1.33K ﹤0.01% 876

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fortitude Family Office's MRVI Position: Q2 2025 in Review

Fortitude Family Office sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 276 shares — an estimated $610 sold.

Fortitude Family Office first reported a position in MRVI in Q2 2024 and held it in 3 quarters. The position peaked at $1.5K in Q4 2024. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • Fortitude Family Office reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • Fortitude Family Office sold 276 Maravai LifeSciences shares in Q2 2025, an estimated $610.
  • Fortitude Family Office first reported a position in Maravai LifeSciences in Q2 2024 and held it in 3 quarters.
  • Fortitude Family Office's Maravai LifeSciences position peaked at $1.5K in Q4 2024.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Fortitude Family Office's 13F filing for Q2 2025, filed 15 Jul 2025.